secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040417
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney posts FY2024 net loss of $163.3M; FDA confirms accelerated approval path for rilparencel
--------------------------------------------------------------------------------

- Net loss before noncontrolling interest $163.3M in 2024 vs $135.4M in 2023; R&D expenses rose 20% to $127.7M.
- Cash and equivalents $358.3M at year-end; secured $140M equity to fund operations into mid-2027.
- FDA confirmed accelerated approval pathway for rilparencel using eGFR slope as potential surrogate endpoint; PROACT 2 discontinued.
- Full Phase 2 REGEN-007 Group 1 data expected Q2 2025; interim June 2024 showed 18-month kidney function stabilization.
- Phase 3 PROACT 1 single study may support BLA; additional FDA meeting details expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/0000950170-25-040417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/prok-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer